Recently, Tanya Dorff, MD, Division Chief of the Genitourinary Disease Program at City of Hope, served as faculty for i3 Health's CME/NCPD-approved activity, Evolving Treatment Concepts and New Data in Advanced Prostate Cancer. Since recording, a plethora of new data and treatment options have been made available for prostate cancer, as well as additional ongoing and future clinical trials to look forward to. In this interview, Dr. Dorff catches us up to speed on these new advancements and share...

Prostate cancer is the most common tumor type among men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Metastatic castration-resistant prostate cancer (CRPC) is the primar...

Androgen deprivation therapy (ADT) is an effective treatment for high-risk prostate cancer in all stages of the disease. However, Ravishankar Jayadevappa, PhD, and colleagues found in a recent population-based study that this commonly used treatment increases diagnoses of dementia and Alzheimer's disease. In this interview with i3 Health, Tanya Dorff, MD, Associate Clinical Professor and Head of the Genitourinary Cancers Program at City of Hope, discusses the study's findings and their potential...